Cerus (CERS) to Release Quarterly Earnings on Wednesday

Cerus (NASDAQ:CERS - Get Free Report) is set to release its earnings data after the market closes on Wednesday, October 30th. Analysts expect Cerus to post earnings of ($0.03) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Cerus (NASDAQ:CERS - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The business had revenue of $45.08 million for the quarter, compared to analyst estimates of $42.50 million. Cerus had a negative net margin of 14.15% and a negative return on equity of 44.27%. During the same quarter last year, the firm earned ($0.07) EPS. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Trading Down 1.2 %

Cerus stock traded down $0.02 during trading hours on Wednesday, reaching $1.61. The stock had a trading volume of 920,596 shares, compared to its average volume of 1,229,691. The stock has a market cap of $297.67 million, a PE ratio of -9.47 and a beta of 1.18. Cerus has a 52 week low of $1.25 and a 52 week high of $2.59. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.51 and a quick ratio of 1.83. The company has a fifty day simple moving average of $1.95 and a 200-day simple moving average of $1.92.

Insider Transactions at Cerus

In other news, CFO Kevin Dennis Green sold 28,385 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares of the company's stock, valued at approximately $1,286,995.70. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Kevin Dennis Green sold 28,385 shares of Cerus stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the transaction, the chief financial officer now directly owns 590,365 shares of the company's stock, valued at $1,286,995.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Richard J. Benjamin sold 21,605 shares of Cerus stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $2.50, for a total transaction of $54,012.50. Following the transaction, the insider now directly owns 438,007 shares of the company's stock, valued at approximately $1,095,017.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company's stock.

Analysts Set New Price Targets

Separately, Stifel Nicolaus dropped their target price on shares of Cerus from $6.00 to $3.00 and set a "buy" rating for the company in a research report on Thursday, October 17th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $3.63.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.